Eli Lilly s Pleasant Prairie facility expansion gets final approval, paving the way for a 3 billion Kenosha County investment ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Eli Lilly's stock dipped slightly by -0.27% to close at $822.51, outperforming the S&P 500’s larger 1.07% drop. Despite a ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

The Department of Health and Human Services (HHS) has filed for summary judgment in its favor regarding lawsuits brought by ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely affected by how medicines are selected for the Medicare drug price negotiation | ...